Bank of America Slashes Leidos Price Target on Healthcare Pressures

What happened

Bank of America downgraded Leidos from buy to neutral and slashed its price target by 37.5% on Wednesday. The firm warned that pressure is building on the company's healthcare portfolio, which had previously been a growth driver. Specifically, the Defense Health Agency - a combat support division of the U.S. Department of Defense - is now working directly with suppliers for the Defense Healthcare Management System Modernization program, bypassing Leidos as an intermediary. This shift threatens a key revenue stream for the company.

Why the stock moved

Shares dropped 11% following the downgrade as investors reassessed Leidos's growth prospects. The sharp reduction in the price target signaled that analysts expect weaker performance from the healthcare segment going forward. The stock closed at $113.58 on Tuesday, below even the revised $125 target. Investor sentiment turned negative as the market digested the potential loss of a business line that had been considered a strong suit for the defense contractor.

Bigger picture

Leidos operates at the intersection of defense, healthcare, and technology services, with significant exposure to U.S. government contracts. The Defense Health Agency's decision to work directly with suppliers reflects a broader trend of government agencies seeking cost efficiencies and more direct vendor relationships. Despite the near-term headwinds, Leidos remains highly profitable and carries no debt. The stock now trades at 10 times trailing earnings, well below its five-year average P/E of 20.6, suggesting the market may have overreacted to a single portfolio challenge.

What investors watch

Investors should monitor upcoming earnings reports for commentary on the healthcare segment's performance and any steps management is taking to offset lost revenue. Watch for updates on contract wins in other divisions, particularly defense and civil services, which could help diversify growth. The company's ability to maintain profitability and its debt-free balance sheet will be key indicators of financial resilience. Any stabilization or recovery in the healthcare business could provide a catalyst for the stock to rebound from current levels.